Literature DB >> 31284781

MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer.

Qian Tang1, Hu Ouyang1, Dongxiu He1,2, Cuiyun Yu1,2, Guotao Tang1,2.   

Abstract

Triple-negative breast cancer (TNBC) is a distinct subtype of breast cancer characterized by high recurrence rates and poor prognosis compared to other breast cancers. MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of various post-transcriptional gene and silence a broad set of target genes. Many recent studies have demonstrated that miRNAs play an important role in the initiation, promotion, malignant conversion, progression, and metastasis of TNBC. Therefore, the aim of this review is to focus on recent advancements of microRNAs-based potential applications in diagnosis, treatment and prognosis of triple-negative breast cancer.

Entities:  

Keywords:  Diagnosis; microRNA; prognosis; treatment; triple-negative breast cancer

Year:  2019        PMID： 31284781     DOI： 10.1080/21691401.2019.1638791

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN： 2169-1401            Impact factor:   5.678


  12 in total

Review 1.  Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology.

Authors:  Asadoor Amirkhani Namagerdi; Danila d'Angelo; Francesca Ciani; Carmelina Antonella Iannuzzi; Francesco Napolitano; Luigi Avallone; Michelino De Laurentiis; Antonio Giordano
Journal:  Front Oncol       Date:  2020-11-12       Impact factor: 6.244

Review 2.  Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets.

Authors:  Ishita Gupta; Balsam Rizeq; Semir Vranic; Ala-Eddin Al Moustafa; Halema Al Farsi
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

3.  MicroRNA-598 inhibits the growth of triple negative breast cancer cells by targeting JAG1.

Authors:  Guohui Han; Xiangdong Bai; Hongchuan Jiang; Qiang He
Journal:  Exp Ther Med       Date:  2021-01-21       Impact factor: 2.447

4.  MiR-21 Is Required for the Epithelial-Mesenchymal Transition in MDA-MB-231 Breast Cancer Cells.

Authors:  Elif Damla Arisan; Ozge Rencuzogullari; Clara Cieza-Borrella; Francesc Miralles Arenas; Miriam Dwek; Sigrun Lange; Pinar Uysal-Onganer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

Review 5.  Epigenetic Alterations in Triple-Negative Breast Cancer-The Critical Role of Extracellular Matrix.

Authors:  Vasiliki Zolota; Vasiliki Tzelepi; Zoi Piperigkou; Helen Kourea; Efthymia Papakonstantinou; Μaria-Ioanna Argentou; Nikos K Karamanos
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

6.  Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.

Authors:  Amal Qattan; Taher Al-Tweigeri; Wafa Alkhayal; Kausar Suleman; Asma Tulbah; Suad Amer
Journal:  Genes (Basel)       Date:  2021-04-09       Impact factor: 4.096

Review 7.  MitomiRs: their roles in mitochondria and importance in cancer cell metabolism.

Authors:  Andrej Rencelj; Nada Gvozdenovic; Maja Cemazar
Journal:  Radiol Oncol       Date:  2021-11-19       Impact factor: 2.991

8.  Highly connected, non-redundant microRNA functional control in breast cancer molecular subtypes.

Authors:  Guillermo de Anda-Jáuregui; Jesús Espinal-Enríquez; Enrique Hernández-Lemus
Journal:  Interface Focus       Date:  2021-06-11       Impact factor: 3.906

9.  Association of the Expression Level of miR-16 with Prognosis of Solid Cancer Patients: A Meta-Analysis and Bioinformatic Analysis.

Authors:  Wanting Zhang; Feixiang Zhou; Danjie Jiang; Yingying Mao; Ding Ye
Journal:  Dis Markers       Date:  2020-07-25       Impact factor: 3.434

Review 10.  Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma.

Authors:  Lisa Linck-Paulus; Claus Hellerbrand; Anja K Bosserhoff; Peter Dietrich
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.